Trade-Ideas LLC identified China Biologic Products ( CBPO) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified China Biologic Products as such a stock due to the following factors:

  • CBPO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $36.0 million.
  • CBPO has traded 53,948 shares today.
  • CBPO is trading at 2.50 times the normal volume for the stock at this time of day.
  • CBPO is trading at a new high 3.01% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in CBPO with the Ticky from Trade-Ideas. See the FREE profile for CBPO NOW at Trade-Ideas

More details on CBPO:

China Biologic Products, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. CBPO has a PE ratio of 32. Currently there are 3 analysts that rate China Biologic Products a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for China Biologic Products has been 246,700 shares per day over the past 30 days. China Biologic has a market cap of $2.9 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.97 and a short float of 3.4% with 1.94 days to cover. Shares are down 25.7% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates China Biologic Products as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Highlights from the ratings report include:
  • CBPO's revenue growth has slightly outpaced the industry average of 19.4%. Since the same quarter one year prior, revenues rose by 21.6%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • CBPO has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 3.71, which clearly demonstrates the ability to cover short-term cash needs.
  • CHINA BIOLOGIC PRODUCTS INC has improved earnings per share by 8.0% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, CHINA BIOLOGIC PRODUCTS INC increased its bottom line by earning $3.27 versus $2.72 in the prior year. This year, the market expects an improvement in earnings ($4.26 versus $3.27).
  • The net income growth from the same quarter one year ago has greatly exceeded that of the S&P 500, but is less than that of the Biotechnology industry average. The net income increased by 13.1% when compared to the same quarter one year prior, going from $23.16 million to $26.20 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.